Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 6, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under IFRS)

Company name	Ajinomoto Co., Inc.
Stock exchange listing	Tokyo Stock Exchange
Stock Code	2802
URL	https://www.ajinomoto.co.jp/company/
Representative	Shigeo Nakamura, Representative Executive Officer & President
For inquiries	Itoomi Watanabe, Corporate Executive & General Manager, Global Finance Department
Telephone	+81-3-5250-8111
Scheduled date of starting payment of dividend	—
Preparation of supplementary materials	Yes
Results briefing	Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Three Months Ended June 30, 2026

(1) Consolidated Operating Results

(Percentages indicate year-on-year changes.)

	Sales		Business profit		Profit before income taxes		Profit	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2026	412,105	13.2	60,116	27.3	54,994	14.4	39,312	12.6
June 30, 2025	364,008	(0.4)	47,236	9.7	48,072	20.7	34,926	30.4

	Profit attributable to owners of the parent company		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Three months ended	Million yen	%	Million yen	%	Yen	Yen
June 30, 2026	36,452	13.1	48,702	97.5	38.11	38.10
June 30, 2025	32,218	34.4	24,664	(65.7)	32.62	32.62

Upon the adoption of IFRS, the Ajinomoto Group has introduced “business profit” as a new profit level that will better enable investors, the Board of Directors, and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continual evaluation of the Group’s business portfolio by the Board of Directors and the Management Committee.

“Business profit” is defined as sales and share of profit of associates and joint ventures minus cost of sales, selling expenses, research and development expenses, and general and administrative expenses. Business profit does not include other operating income or other operating expenses.

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the parent company	Ownership ratio attributable to owners of the parent company
As of	Million yen	Million yen	Million yen	%
June 30, 2026	1,940,438	848,397	774,552	39.9
March 31, 2026	1,812,346	844,275	770,819	42.5

(3) Consolidated Cash Flows

	Net cash provided by operating activities	Net cash used in investing activities	Net cash provided by financing activities	Cash and cash equivalents at end of period
Three months ended	Million yen	Million yen	Million yen	Million yen
June 30, 2026	18,409	(22,542)	93,639	196,979
June 30, 2025	30,419	(28,983)	34,010	197,921

2. Cash Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31,2026	—	24.00	—	24.00	48.00
Fiscal year ending March 31,2027	—				
Fiscal year ending March 31, 2027 (Forecast)		25.00	—	25.00	50.00

Revisions from the last forecast released: None

3. Forecast for the Fiscal Year Ending March 31, 2027

(Percentages indicate year-on-year changes.)

	Sales		Business profit		Profit attributable to owners of the parent company		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Yen
Full-year	1,732,000	9.4	202,000	11.5	123,500	(8.3)	129.84

Revisions from the last forecast released: Yes

Notes

(1) Changes in significant subsidiaries during the period: None

(2) Changes in accounting policies and accounting estimates

(i) Changes in accounting policies as required by IFRS: None

(ii) Other changes in accounting policies: None

(iii) Changes in accounting estimates: None

(3) Number of shares outstanding (ordinary shares)

(i) Number of shares outstanding at end of period (including treasury stock)

As of June 30, 2026	977,735,616
As of March 31, 2026	977,735,616

(ii) Number of shares in treasury stock at end of period

As of June 30, 2026	23,173,875
As of March 31, 2026	19,290,839

(iii) Average number of shares during period

Three months ended June 30, 2026	956,451,886
Three months ended June 30, 2025	987,719,450

Note: The number of shares in treasury stock at the end of the period includes the Company's shares held by the director's remuneration BIP trust (As of June 30, 2026: 792,000 shares. As of March 31, 2026: 792,000 shares), which was adopted along with the introduction of a Medium-term Stock-based Incentives (MTI) plan for executive officers based on the Company's medium-term earnings performance for the directors and others. In addition, these Company's shares are included in the treasury stock which is deducted from the number of shares outstanding at the end of the period when calculating the average number of shares during the period.

Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

Appropriate use of forecasts and other notes

Disclaimer regarding forward-looking statements and other information

Forward-looking statements, such as business forecasts, included in this document are based on management's estimates, assumptions, and projections at the time of release. These statements do not promise nor represent a commitment by the Company to achieve these forecasts. Actual operating results may differ significantly due to various factors. For more information regarding earnings forecasts, see page 5, *"1. Qualitative Information on the Three-month Consolidated Results, (1) Overview of Operating Results*."

Where to obtain supplementary materials

Supplementary materials will be posted on the Company's website on Thursday, August 6, 2026.

Table of contents

1. Qualitative Information on the Three-month Consolidated Results

Upon the adoption of IFRS, the Ajinomoto Group has introduced "business profit" as a new profit level that will better enable investors, the Board of Directors, and the Management Committee to grasp the core business results and future outlook of each business while also facilitating continual evaluation of the Group's business portfolio by the Board of Directors and the Management Committee. "Business profit" is defined as sales and share of profit of associates and joint ventures minus cost of sales, selling expenses, research and development expenses, and general and administrative expenses. Business profit does not include other operating income or other operating expenses.

(1) Overview of Operating Results

In the three months ended June 30, 2026, the Company's consolidated sales increased 13.2% year on year, or ¥48.0 billion, to ¥412.1 billion. This was mainly due to increases in sales in the Seasonings and Foods segment and the Healthcare and Others segment. Business profit increased 27.3% year on year, or ¥12.8 billion, to ¥60.1 billion primarily due to the increases in revenue in the Healthcare and Others segment and the Seasonings and Foods segment. Profit attributable to owners of the parent company totaled ¥36.4 billion, up 13.1% year on year, or ¥4.2 billion, primarily as a result of higher business profit.

After reevaluating the current business environment, including the impact of escalating tensions in the Middle East, which had not been reflected in the previous forecast, as well as economic conditions, sales trend, raw material costs, and the initiatives being taken by each business division, the Company has revised its forecast for sales, business profit, and profit attributable to owners of the parent company from the forecast previously announced on May 7, 2026.

While the sales forecast for the Seasonings and Foods and the Frozen Foods segments remained unchanged, the Company has increased its sales forecast for the Healthcare and Others segment by ¥9.0 billion from the previous forecast, reflecting strong demand for electronic materials used in high-performance circuit boards for AI, server, and network applications. As a result, the total sales forecast was increased by ¥9.0 billion to ¥1,732.0 billion. The progress rate of sales against the revised forecast is 23.8%.

The Company has raised its total business profit forecast by ¥5.0 billion from the previous forecast to ¥202.0 billion, due to an upward revision of ¥5.0 billion in business profit in the Healthcare and Others segment reflecting strong sales as described above. Business profit in the Seasonings and Foods segment and the Frozen Foods segment is unchanged from the previous forecast. The progress rate of business profit against the revised forecast is 29.8%.

The Company has raised its forecast for profit attributable to owners of the parent company by ¥3.5 billion from the previous forecast to ¥123.5 billion, mainly reflecting the upward revision in business profit. The progress rate of profit attributable to owners of the parent company against the revised forecast is 29.5%. The forecast is based on an exchange rate of ¥150 to US$1.

For details on the revised forecast, please also refer to the "Notice of Revision to Full-Year Consolidated Performance Forecast" released today.

Overview by segment

Sales and business profit by segment are summarized below.

Versus previous year results (Billions of yen)

	Sales			Business profit		
	FY2026 Q1	YoY change	% change	FY2026 Q1	YoY change	% change
Seasonings and Foods	238.7	25.3	11.9%	41.0	4.7	13.0 %
Frozen Foods	72.5	3.8	5.6%	2.1	(0.6)	(23.2)%
Healthcare and Others	97.0	18.0	22.8%	25.1	9.7	63.3 %
Other	3.7	0.8	29.8%	1.6	(0.2)	(14.0)%
Shared companywide expenses	—	—	—	(9.9)	(0.6)	7.2 %
Total	412.1	48.0	13.2%	60.1	12.8	27.3 %

Versus the forecast (Billions of yen)

	Sales			Business profit		
	FY2026 Q1	Forecast for the year	YTD progress	FY2026 Q1	Forecast for the year	YTD progress
Seasonings and Foods	238.7	998.6	23.9%	41.0	145.9	28.1 %
Frozen Foods	72.5	310.6	23.4%	2.1	12.1	17.7 %
Healthcare and Others	97.0	406.8	23.8%	25.1	85.0	29.6 %
Other	3.7	15.8	23.6%	1.6	5.1	32.4 %
Shared companywide expenses	—	—	—	(9.9)	(46.2)	21.5 %
Total	412.1	1,732.0	23.8%	60.1	202.0	29.8 %

(i) Seasonings and Foods

Seasonings and Foods segment sales increased 11.9% year on year, or ¥25.3 billion, to ¥238.7 billion, mainly owing to the effect of currency translation and sales growth. Segment business profit increased 13.0% year on year, or ¥4.7 billion, to ¥41.0 billion, due primarily to the effect of increased revenue.



Main factors affecting segment sales

Sauce & Seasonings: Overall increase in revenue.
Japan: Revenue was level with the previous year.
Overseas: Increase in revenue due to currency translation and an increase in sales volume.

Quick Nourishment: Overall increase in revenue.
Japan: Overall increase in revenue primarily due to increased revenue for coffee products and soups.
Overseas: Large increase in revenue due to currency translation and increased sales.

Solution & Ingredients: Increase in revenue primarily due to increased sales of restaurant and industrial-use products and currency translation.

Main factors affecting segment profits

Sauce & Seasonings: Overall large increase in profit.
Japan: Increase in profit primarily due to decreased SGA expenses.
Overseas: Large increase in profit primarily due to the effect of increased revenue.

Quick Nourishment: Overall large increase in profit.
Japan: Large increase in profit primarily due to the effect of increased revenue.
Overseas: Decrease in profit primarily due to increased strategic expenses, despite increase in revenue.

Solution & Ingredients: Overall decrease in profit due to decreased profit for umami seasonings for processed food manufacturers, despite increased profit for restaurant and industrial-use products.

(ii) Frozen Foods

Frozen Foods segment sales increased 5.6% year on year, or ¥3.8 billion, to ¥72.5 billion, primarily owing to currency translation. Segment business profit decreased 23.2% year on year, or ¥0.6 billion, to ¥2.1 billion.

Main factors affecting segment sales

Overall increase in revenue primarily due to currency translation.

Main factors affecting segment profits

Overall large decrease in profit.

(iii) Healthcare and Others

Healthcare and Others segment sales increased 22.8% year on year, or ¥18.0 billion, to ¥97.0 billion, owing to strong sales of electronic materials and other factors. Segment business profit increased 63.3% year on year, or ¥9.7 billion, to ¥25.1 billion, due primarily to the effect of significantly higher revenue in electronic materials.



Main factors affecting segment sales

Bio-Pharma Services & Ingredients: Increase in revenue due to currency translation and increased sales of amino acids for pharmaceuticals and foods.

Functional Materials (electronic materials and others): Large increase in revenue due to strong sales of electronic materials.

Others: Overall increase in revenue.

Main factors affecting segment profits

Bio-Pharma Services & Ingredients: Overall large increase in profit due to increase in profit for both amino acids for pharmaceutical and foods and Bio-Pharma Services (CDMO services).

Functional Materials (electronic materials and others): Large increase in profit accompanying large increase in revenue.

Others: Overall profit was level with the previous year.

(iv) Other

In the Other segment, sales increased 29.8% year on year, or ¥0.8 billion, to ¥3.7 billion. Segment business profit decreased 14.0% year on year, or ¥0.2 billion, to ¥1.6 billion.

(2) Overview of Financial Position

As of June 30, 2026, the Company's consolidated total assets stood at ¥1,940.4 billion, an increase of ¥128.0 billion from ¥1,812.3 billion at the end of the previous fiscal year on March 31, 2026. The main reasons for the change were increases in cash and cash equivalents and inventories.

Total liabilities came to ¥1,092.0 billion, ¥123.9 billion more than the ¥968.0 billion at the end of the previous fiscal year. This was mainly due to an increase in interest bearing debt. Interest bearing debt totaled ¥623.7 billion, an increase of ¥141.0 billion from the end of the previous fiscal year, mainly due to the issuance of commercial papers.

Total equity came to ¥848.3 billion, ¥4.1 billion more than the total at the end of the previous fiscal year. Despite a decrease due to the acquisition of treasury stock, this was mainly due to increases in retained earnings and exchange differences on translation of foreign operations resulting from the depreciation of the yen. Equity attributable to owners of the parent company, which is total equity minus non-controlling interests, totaled ¥774.5 billion, and the equity ratio attributable to owners of the parent company was 39.9%.

(3) Overview of Cash Flows

The overview of cash flows for the three months ended June 30, 2026 is as follows:

Net cash provided by operating activities totaled ¥18.4 billion during the three months ended June 30, 2026, compared with ¥30.4 billion during the three months ended June 30, 2025. The main factors included ¥54.9 billion in profit before income taxes and ¥23.4 billion in depreciation and amortization, offset by a ¥28.6 billion increase in inventories, and ¥16.7 billion in income taxes paid.

Net cash used in investing activities came to ¥22.5 billion during the three months ended June 30, 2026, compared with ¥28.9 billion during the three months ended June 30, 2025. The main factors included ¥11.7 billion in proceeds from sale and redemption of financial assets offset by ¥33.4 billion in purchase of property, plant and equipment, and intangible assets.

Net cash provided by financing activities was ¥93.6 billion during the three months ended June 30, 2026, compared with ¥34.0 billion during the three months ended June 30, 2025. The main factors included ¥140.0 billion in net proceeds from issuance of commercial papers, which offset ¥22.5 billion in dividends paid and ¥19.3 billion in purchase of treasury stock.

As a result of the foregoing, cash and cash equivalents as of June 30, 2026 totaled ¥196.9 billion.

(4) Analysis of Capital Resources and Liquidity

(i) Liquidity

During the three months ended June 30, 2026, the Company ensured adequate short-term liquidity on hand through funding methods that mainly consisted of committed credit lines, overdraft facilities, and commercial paper issuance facilities.

Moreover, in addition to maintaining an adequate ratio of liquidity on hand, the Company ensured funding security through committed credit lines concluded with its main banks. As of June 30, 2026, the unused amount of committed credit lines was ¥200.0 billion in Japanese yen and US$100 million in foreign currency. Furthermore, the Company provides a loan facility to respond to temporary cash shortages at overseas consolidated subsidiaries with a high possibility of liquidity risks.

(ii) Fund Procurement

In the three months ended June 30, 2026, the Company raised funds mainly through the issuance of commercial papers in order to fund its operations, taking into consideration the balance between direct and indirect finance from the perspective of funding costs and risk diversification, and the balance between long-term and short-term funding.

(iii) Use of Funds

During the three months ended June 30, 2026, funds were primarily used to finance business operations.

2. Condensed Consolidated Financial Statements and Notes

(1) Condensed Consolidated Statements of Financial Position

(Millions of yen)

	As of June 30, 2026	As of March 31, 2026
Assets		
Current assets		
Cash and cash equivalents	196,979	106,693
Trade and other receivables	202,837	194,221
Other financial assets	38,259	46,670
Inventories	349,747	318,632
Income taxes receivable	10,571	7,656
Others	34,491	30,294
Subtotal	832,888	704,170
Assets of disposal groups classified as held for sale	—	—
Total current assets	832,888	704,170
Non-current assets		
Property, plant and equipment	650,572	647,381
Intangible assets	91,448	92,231
Goodwill	125,438	124,051
Investments in associates and joint ventures	139,986	138,571
Long-term financial assets	49,176	54,675
Deferred tax assets	12,539	13,844
Others	38,388	37,419
Total non-current assets	1,107,549	1,108,176
Total assets	1,940,438	1,812,346

(Millions of yen)

	As of June 30, 2026	As of March 31, 2026
Liabilities		
Current liabilities		
Trade and other payables	293,827	303,960
Short-term borrowings	7,069	6,350
Commercial papers	140,000	—
Current portion of bonds	29,991	29,988
Current portion of long-term borrowings	4,048	4,095
Other financial liabilities	12,296	11,625
Short-term employee benefits	45,130	51,585
Provisions	1,547	6,362
Income taxes payable	21,312	18,659
Others	20,093	16,435
Subtotal	575,318	449,063
Liabilities of disposal groups classified as held for sale	—	—
Total current liabilities	575,318	449,063
Non-current liabilities		
Corporate bonds	174,531	174,512
Long-term borrowings	206,280	206,410
Other financial liabilities	64,960	64,810
Long-term employee benefits	33,995	33,943
Provisions	6,872	6,812
Deferred tax liabilities	26,081	28,326
Others	3,999	4,191
Total non-current liabilities	516,722	519,007
Total liabilities	1,092,040	968,070
Equity		
Common stock	79,863	79,863
Capital surplus	209	—
Treasury stock	(86,710)	(67,337)
Retained earnings	604,540	587,856
Other components of equity	176,649	170,436
Other components of equity related to disposal groups classified as held for sale	—	—
Equity attributable to owners of the parent company	774,552	770,819
Non-controlling interests	73,845	73,456
Total equity	848,397	844,275
Total liabilities and equity	1,940,438	1,812,346

(2) Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Statements of Income

(Millions of yen)

	Three months ended June 30, 2026	Three months ended June 30, 2025
Sales	412,105	364,008
Cost of sales	(247,475)	(224,999)
Gross profit	164,630	139,008
Share of profit of associates and joint ventures	2,688	3,128
Selling expenses	(56,183)	(48,992)
Research and development expenses	(7,973)	(7,345)
General and administrative expenses	(43,044)	(38,562)
Business profit	60,116	47,236
Other operating income	1,841	5,293
Other operating expenses	(6,062)	(3,149)
Operating profit	55,895	49,380
Financial income	2,426	2,247
Financial expenses	(3,327)	(3,555)
Profit before income taxes	54,994	48,072
Income taxes	(15,681)	(13,145)
Profit	39,312	34,926
Profit attributable to:		
Owners of the parent company	36,452	32,218
Non-controlling interests	2,860	2,708
Earnings per share (yen):		
Basic	38.11	32.62
Diluted	38.10	32.62

Condensed Consolidated Statements of Comprehensive Income

(Millions of yen)

	Three months ended June 30, 2026	Three months ended June 30, 2025
Profit	39,312	34,926
Other comprehensive income (Net of related tax effects)		
Items that will not be reclassified to profit or loss:		
Net gain (loss) on revaluation of financial assets measured at fair value through other comprehensive income	(1,221)	1,356
Remeasurements of defined benefit pension plans	659	901
Share of other comprehensive income (loss) of associates and joint ventures	(65)	55
Items that may be reclassified subsequently to profit or loss:		
Cash flow hedges	323	(204)
Hedge surplus	(48)	(92)
Exchange differences on translation of foreign operations	9,882	(11,979)
Share of other comprehensive loss of associates and joint ventures	(139)	(299)
Other comprehensive income (Net of related tax effects)	9,389	(10,262)
Comprehensive income	48,702	24,664
Comprehensive income attributable to:		
Owners of the parent company	46,000	21,692
Non-controlling interests	2,701	2,971

(3) Condensed Consolidated Statements of Cash Flows

(Millions of yen)

	Three months ended June 30, 2026	Three months ended June 30, 2025
Cash flows from operating activities		
Profit before income taxes	54,994	48,072
Depreciation and amortization	23,495	21,031
Impairment loss and gain on reversal of impairment loss	635	321
Increase (decrease) in employee benefits	(6,120)	(7,311)
Increase (decrease) in provisions	(4,838)	(3,260)
Interest and dividend income	(1,732)	(1,916)
Interest expense	2,044	1,801
Share of profit of associates and joint ventures	(2,688)	(3,128)
Loss on sale and retirement of property, plant and equipment, and intangible assets	941	816
Decrease (increase) in trade and other receivables	(7,475)	(395)
Increase (decrease) in trade and other payables	1,501	3,699
Decrease (increase) in inventories	(28,633)	(18,424)
Increase (decrease) in other assets and liabilities	3,056	5,896
Others	(1,391)	(7,877)
Subtotal	33,789	39,325
Interest and dividends received	3,246	3,148
Interest paid	(1,895)	(1,623)
Income taxes paid	(16,731)	(10,431)
Net cash provided by operating activities	18,409	30,419
Cash flows from investing activities		
Purchase of property, plant and equipment, and intangible assets	(33,412)	(30,393)
Proceeds from sale of property, plant and equipment, and intangible assets	391	117
Purchase of financial assets	(1,076)	(4,059)
Proceeds from sale and redemption of financial assets	11,759	3,422
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	—	1,995
Others	(204)	(66)
Net cash used in investing activities	(22,542)	(28,983)

(Millions of yen)

	Three months ended June 30, 2026	Three months ended June 30, 2025
Cash flows from financing activities		
Net change in short-term borrowings	582	2,100
Net change in commercial papers	140,000	110,000
Repayments of long-term borrowings	(231)	(7,835)
Dividends paid	(22,537)	(18,811)
Dividends paid to non-controlling interests	(2,504)	(2,588)
Purchase of treasury stock	(19,373)	(46,619)
Repayments of lease liabilities	(2,296)	(2,255)
Others	—	19
Net cash provided by financing activities	93,639	34,010
Effect of currency rate changes on cash and cash equivalents	779	(2,300)
Net change in cash and cash equivalents	90,285	33,145
Cash and cash equivalents at beginning of period	106,693	164,776
Cash and cash equivalents at end of period	196,979	197,921

(4) Notes to Condensed Consolidated Financial Statements

Going Concern Assumption

Not applicable

Significant Changes in Equity Attributable to Owner of the Parent Company

Not applicable

Segment Information

(1) Overview of reportable segments

The Group's reportable segments are categorized primarily by product lines. There are three reportable segments: Seasonings and Foods, Frozen Foods, and Healthcare and Others.

Each reportable segment is a component of the Group for which separate financial information is available and evaluated regularly by the Management Committee in determining the allocation of management resources and in assessing performance.

The product categories belonging to each reportable segment are as follows:

Reportable Segments	Details	Main Products
Seasonings & Foods	Sauce & Seasonings	Umami seasoning *AJI-NO-MOTO®*, *HON-DASHI®*, *Cook Do®*, *Ajinomoto KK Consommé*, *Pure Select® Mayonnaise,* *Ros Dee®* (flavor seasoning), *Masako®* (flavor seasoning), *Aji-ngon®* (flavor seasoning), *Sazón®* (flavor seasoning), *Sajiku®* (menu-specific seasoning), *CRISPY FRY®* (menu-specific seasoning), etc.
	Quick Nourishment	*Knorr® Cup Soup*, *YumYum®* (instant noodles), *Birdy®* (coffee beverage), *Birdy® 3in1* (powdered drink), *Blendy®* brand products (*CAFÉ LATORY®*, stick coffee, etc.), *MAXIM®* brand products, *Chotto Zeitakuna Kohiten®* brand products, various gift sets, office supplies (coffee vending machines, tea servers), etc.
	Solution & Ingredients	Umami seasoning *AJI-NO-MOTO®* for foodservice and processed food manufacturers in Japan, Seasonings and processed foods for foodservice, Seasonings for processed foods (savory seasonings, enzyme *ACTIVA®*), Delicatessen products, Bakery products, Nucleotides, Sweeteners (aspartame for industrial use, etc.), and others
Frozen Foods	Frozen Foods	Chinese dumplings (*Gyoza, POT STICKERS*, etc.), Cooked rice (*THE CHA-HAN, CHICKEN FRIED RICE*, etc.), Noodles (*YAKISOBA, RAMEN*, etc.), Sweets (cakes for restaurant and industrial-use, *MACARON*, etc.), Shumai (*THE SHUMAI, Ebi shumai (shrimp dumpling)*, etc.), Processed chicken (*Yawaraka Wakadori Kara-Age* (fried chicken), *THE KARAAGE*, etc.), and others
Healthcare & Others	Amino Acids for Pharmaceuticals & Foods	Amino Acids for Pharmaceuticals and Foods, culture media
	Bio-Pharma Services (CDMO services)	Contract development and manufacturing services of pharmaceutical intermediates and active ingredients and others
	Functional Materials (electronic materials and others)	Electronic materials (interlayer insulating material for semiconductor packages *ABF™*, etc.), Functional materials (adhesive *PLENSET®*, magnetic materials *AFTINNOVA® Magnetic Film*, etc.), activated carbon, release paper, etc.
	Others	Feed-use amino acids, Sports nutrition (Supplement (*amino VITAL®*), etc.), Personal care ingredients (an amino acid-based surfactant (*Amisoft®*), and amino acid-based oil and powder for use in makeup (*Eldew®* and *Amihope®*, respectively), etc.), Medical foods, Crop services, etc.

(2) Sales and profits by segment
The Group’s sales and profits by reportable segment are as follows:
Inter-segment sales and transfers are primarily based on transaction prices with third parties.

Three months ended June 30, 2026 (April 1, 2026 to June 30, 2026)

(Millions of yen)

	Reportable Segments			Other[1]	Total sales	Adjustments[2]	As included in consolidated statements of income
	Seasonings and Foods	Frozen Foods	Healthcare and Others				
Sales							
Sales to third parties	238,744	72,591	97,032	3,737	412,105	—	412,105
Inter-segment sales and transfers	2,653	186	1,221	7,248	11,310	(11,310)	—
Total sales	241,398	72,778	98,254	10,986	423,416	(11,310)	412,105
Share of profit of associates and joint ventures	1,062	—	(47)	1,673	2,688	—	2,688
Segment profit or loss (Business profit or loss)	41,044	2,160	25,171	1,656	70,032	(9,915)	60,116
				Other operating income			1,841
				Other operating expenses			(6,062)
				Operating profit			55,895
				Financial income			2,426
				Financial expenses			(3,327)
				Profit before income taxes			54,994

1. Other includes the tie-up and other service-related businesses.
2. Adjustments of segment profit or loss are shared companywide expenses, which are expenses not attributable to specific reportable segments. Shared companywide expenses mainly relate to the parent company’s administrative divisions.

Three months ended June 30, 2025 (April 1, 2025 to June 30, 2025)

(Millions of yen)

	Reportable Segments			Other[1]	Total sales	Adjustments[2]	As included in consolidated statements of income
	Seasonings and Foods	Frozen Foods	Healthcare and Others				
Sales							
Sales to third parties	213,387	68,752	78,989	2,878	364,008	—	364,008
Inter-segment sales and transfers	2,097	126	1,434	6,759	10,418	(10,418)	—
Total sales	215,485	68,879	80,424	9,637	374,427	(10,418)	364,008
Share of profit of associates and joint ventures	1,161	—	(35)	2,002	3,128	—	3,128
Segment profit or loss (Business profit or loss)	36,332	2,812	15,412	1,926	56,484	(9,247)	47,236
				Other operating income			5,293
				Other operating expenses			(3,149)
				Operating profit			49,380
				Financial income			2,247
				Financial expenses			(3,555)
				Profit before income taxes			48,072

1. Other includes the tie-up and other service-related businesses.
2. Adjustments of segment profit or loss are shared companywide expenses, which are expenses not attributable to specific reportable segments. Shared companywide expenses mainly relate to the parent company’s administrative divisions.

Significant Subsequent Events

Not applicable